<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03729830</url>
  </required_header>
  <id_info>
    <org_study_id>92249986</org_study_id>
    <nct_id>NCT03729830</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of Open Irrigated Ablation Catheters With High Resolution Mapping to Treat Paroxysmal Atrial Fibrillation</brief_title>
  <acronym>INTERRUPT AF</acronym>
  <official_title>Prospective Evaluation of Open Irrigated Ablation Catheters With High Resolution Mapping to Treat Paroxysmal Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To obtain data for the Rhythmia™ Mapping System in conjunction with Boston Scientific&#xD;
      Open-Irrigated (OI) Catheters for ablation of Paroxysmal Atrial Fibrillation (PAF) according&#xD;
      to current international and local guidelines.&#xD;
&#xD;
      Primary objective: To assess acute and long-term outcomes for the Rhythmia Mapping System in&#xD;
      conjunction with Boston Scientific Open-Irrigated Ablation Catheters to treat de novo&#xD;
      Paroxysmal Atrial Fibrillation. De Novo PAF is defined as subjects undergoing first ablation&#xD;
      procedure for PAF with no prior left atrial ablation (RF, Cryo, Surgical).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY OBJECTIVE(S) -- To obtain data for the Rhythmia™ Mapping System in conjunction with&#xD;
      Boston Scientific Open-Irrigated (OI) Catheters for ablation of Paroxysmal Atrial&#xD;
      Fibrillation (PAF) according to current international and local guidelines.&#xD;
&#xD;
      PRIMARY OBJECTIVE -- To assess acute and long-term outcomes for the Rhythmia Mapping System&#xD;
      in conjunction with Boston Scientific Open-Irrigated Ablation Catheters to treat de novo&#xD;
      Paroxysmal Atrial Fibrillation. De Novo PAF is defined as subjects undergoing first ablation&#xD;
      procedure for PAF with no prior left atrial ablation (RF, Cryo, Surgical).&#xD;
&#xD;
      INDICATION(S) FOR USE -- Study devices will be used per approved Indications for Use for each&#xD;
      geography.&#xD;
&#xD;
      DEVICES / SYSTEM USED IN THE STUDY -- The study will include the following Boston Scientific&#xD;
      Open-Irrigated Catheters in geographies where commercially approved for PAF ablation:&#xD;
&#xD;
        -  Blazer Open-Irrigated Ablation Catheter&#xD;
&#xD;
        -  IntellaNav Open-Irrigated Ablation Catheter&#xD;
&#xD;
        -  IntellaNav MiFi Open-Irrigated Ablation Catheter&#xD;
&#xD;
        -  IntellaTip MiFi Open-Irrigated Ablation Catheter&#xD;
&#xD;
        -  Rhythmia Mapping System Gen 1or Rhythmia HDx, equipped with Software 1.4 or any&#xD;
           successive commercially approved versions.&#xD;
&#xD;
        -  IntellaMap Orion Catheter&#xD;
&#xD;
      CONTROL DEVICE -- There are no control devices in this study&#xD;
&#xD;
      STUDY DESIGN -- Prospective, non-randomized, multicenter (global), post approval clinical&#xD;
      study (PAS). All subjects fitting the enrollment criteria, signing the consent and undergoing&#xD;
      the index procedure with the study devices will be followed up for three years to complete&#xD;
      the PAS design mandated from the FDA to collect post-market data for Boston Scientific&#xD;
      Open-Irrigated Catheters and will be followed for three years.&#xD;
&#xD;
      PLANNED NUMBER OF SUBJECTS -- The study will enroll 415 subjects.&#xD;
&#xD;
      PLANNED NUMBER OF SITES / COUNTRIES -- The study is global (US, EU, Asia-Pacific) with 25-50&#xD;
      centers. A minimum of 50% of the sites will be selected from the US. No study site will be&#xD;
      allowed to contribute more than 41 subjects (10% of the 415 enrollments requirement).&#xD;
&#xD;
      FOLLOW-UP SCHEDULE -- Study Follow-ups are at: pre-discharge, 1 month (phone check), 3 months&#xD;
      (blanking period), 6 months (phone check), 12 months, 24 months and 36 months.&#xD;
&#xD;
      STUDY DURATION -- Study is expected to be completed in approximately five years (12-24 month&#xD;
      enrollment period with three year follow-up).&#xD;
&#xD;
      PARTICIPANT DURATION -- The study duration for each subject is expected to be approximately&#xD;
      three years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 4, 2019</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety event-free rate</measure>
    <time_frame>12 months</time_frame>
    <description>The primary safety endpoint is defined as the safety event-free rate at 12 months post-procedure.&#xD;
Primary safety events will consist of a composite of acute primary safety events (events occurring within seven days post-procedure or hospital discharge, whichever is later), and chronic primary safety events (events occurring through 3 or 12 months post-procedure).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event Free Rate (Primary)</measure>
    <time_frame>12 Months</time_frame>
    <description>The primary effectiveness endpoint is defined as the event-free rate at 12 months post-procedure.&#xD;
Primary effectiveness events are defined as:&#xD;
Acute procedural failure&#xD;
More than one repeat procedure during the blanking period (90 days post index procedure)&#xD;
Documented atrial fibrillation, or new onset of atrial flutter or atrial tachycardia event (≥ 30 seconds in duration from an event monitor or Holter, or from a 10 second 12-lead EKG) between 91 days and 365 days post index procedure&#xD;
Any of the following interventions for atrial fibrillation, or new onset of atrial flutter or atrial tachycardia between 91 days and 365 days post index procedure:&#xD;
Repeat procedure&#xD;
Cardioversion&#xD;
Prescribed any AAD*&#xD;
AADs for endpoint will consist of all Class I/III and any Class II/IV medications taken for control of AF/AT/AFL recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event Free Rate (Secondary)</measure>
    <time_frame>12 Months</time_frame>
    <description>The secondary effectiveness endpoint is defined as the event-free at 12 months post-procedure.&#xD;
Secondary effectiveness events are defined as:&#xD;
Acute procedural failure&#xD;
More than one repeat procedure during the blanking period (90 days post index procedure)&#xD;
Documented symptomatic atrial fibrillation, or new onset of atrial flutter or atrial tachycardia event (≥ 30 seconds in duration from an event monitor or Holter, or from a 10 second 12-lead EKG) between 91 days and 365 days post index procedure&#xD;
Any of the following interventions for atrial fibrillation, or new onset of atrial flutter or atrial tachycardia between 91 days and 365 days post index procedure:&#xD;
Repeat procedure&#xD;
Cardioversion&#xD;
Prescribed a higher dose of any AAD* documented at baseline&#xD;
Prescribed a new AAD* not documented at baseline&#xD;
AADs for endpoint will consist of all Class I/III and any Class II/IV medications taken for control of AF/AT/AFL recurrence</description>
  </secondary_outcome>
  <enrollment type="Anticipated">415</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Boston Scientific Open Irrigated Ablation Catheters</intervention_name>
    <description>The BSC Open-Irrigated catheters are designed to deliver RF energy to catheter tip electrode for cardiac ablation. The BSC OI catheters incorporate an open-irrigated cooling mechanism through a tip that is partitioned into two chambers. The proximal chamber circulates normal saline (0.9 %) within the tip to cool the proximal electrode and mitigate overheating while the distal chamber allows the fluid to flow through six irrigation holes into the patient's vasculature, thereby cooling the tip/tissue interface.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects included in the INTERRUPT AF study should be selected from the investigator's&#xD;
        general patient population indicated for catheter ablation of PAF.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. History of recurrent symptomatic Paroxysmal Atrial Fibrillation, defined as AFib that&#xD;
             terminates spontaneously or with intervention within seven days of onset. Minimum&#xD;
             documentation includes a physician's note indicating recurrent self-terminating Atrial&#xD;
             Fibrillation AND one electrocardiographically documented AF episode within 6 months&#xD;
             prior to enrollment.&#xD;
&#xD;
          2. Subjects who are eligible for an ablation procedure for Paroxysmal Atrial Fibrillation&#xD;
             with the Rhythmia Mapping system according to current international and local&#xD;
             guidelines&#xD;
&#xD;
          3. Subjects who are eligible for an ablation procedure for Paroxysmal Atrial Fibrillation&#xD;
             with a Boston Scientific Open-Irrigated Ablation Catheter according to current&#xD;
             international and local guidelines&#xD;
&#xD;
          4. Subjects who are willing and capable of providing informed consent&#xD;
&#xD;
          5. Subjects who are willing and capable of participating in all testing associated with&#xD;
             this clinical investigation at an approved clinical investigational center&#xD;
&#xD;
          6. Subjects whose age is 20 years or above, or who are of legal age to give informed&#xD;
             consent specific to state and national law.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects enrolled in any other concurrent clinical study, with the exception of local&#xD;
             mandatory governmental registries and observational studies/registries, without the&#xD;
             written approval from Boston Scientific&#xD;
&#xD;
          2. Subjects unable or unwilling to complete follow-up visits and examination for the&#xD;
             duration of the study&#xD;
&#xD;
          3. Subjects who have undergone any previous left atrial cardiac ablation (RF, Cryo,&#xD;
             surgical)&#xD;
&#xD;
          4. Subjects who have undergone any cardiac ablation within 30 days prior to enrollment&#xD;
&#xD;
          5. Unrecovered/unresolved Adverse Events from any previous invasive procedure&#xD;
&#xD;
          6. Life expectancy &lt;= three years per physician opinion&#xD;
&#xD;
          7. Women of childbearing potential who are, or plan to become, pregnant during the time&#xD;
             of the study (method of assessment upon physician's discretion)&#xD;
&#xD;
          8. Known cardiac thrombus within 60 days prior to enrollment&#xD;
&#xD;
          9. History of CVA, TIA or PE within 90 days prior to enrollment&#xD;
&#xD;
         10. Implanted pacemaker, ICD, or CRT leads within 90 days prior to enrollment&#xD;
&#xD;
         11. Implanted Left atrial appendage closure device prior to the index procedure&#xD;
&#xD;
         12. Prosthetic mitral or tricuspid heart valves (subjects with successful mitral valve&#xD;
             repair allowed- annular ring constitutes repair)&#xD;
&#xD;
         13. Left atrial diameter greater than 5.5cm&#xD;
&#xD;
         14. Documented or suspected stenosis of any pulmonary veins.&#xD;
&#xD;
         15. Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible&#xD;
             or non-cardiac cause.&#xD;
&#xD;
         16. Contraindication for anticoagulation&#xD;
&#xD;
         17. Clinically significant mitral valve regurgitation or stenosis per investigator&#xD;
             discretion.&#xD;
&#xD;
         18. Any cardiac surgery ≤ 90 days from consent date.&#xD;
&#xD;
         19. Any electrocardiographically documented episode of Persistent AFib, defined as AFib&#xD;
             lasting longer than 7 days from onset.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oussama Wazni</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rami Guirguis</last_name>
    <phone>919-374-3388</phone>
    <email>rami.guirguis@bsci.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarfaraz Taher</last_name>
    <phone>651-582 5320</phone>
    <email>Sarfaraz.Taher@bsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Vines</last_name>
      <phone>205-975-4335</phone>
      <email>jsnowden@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>William Maddox</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Torrance Memorial Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaquelina Patti</last_name>
      <phone>310-257-5781</phone>
      <email>jaquelina.patti@tmmc.com</email>
    </contact>
    <investigator>
      <last_name>Sang Yong Ji</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Broward General Medical Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>AdventHealth Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leann Goodwin</last_name>
      <phone>407-303-8059</phone>
      <email>leann.goodwin@adventhealth.com</email>
    </contact>
    <investigator>
      <last_name>Naushad Shaik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Lukes Idaho Cardiology Associates</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon LaMott</last_name>
      <phone>208-388-7216</phone>
      <email>lamotts@slhs.org</email>
    </contact>
    <investigator>
      <last_name>Marcos Daccarett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Hart</last_name>
      <phone>773-702-0535</phone>
      <email>thart@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Hemal Nayak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. John's Hospital</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62769</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Bainter</last_name>
      <phone>217492910029142</phone>
      <email>lbainter@prairieresearch.com</email>
    </contact>
    <investigator>
      <last_name>Ziad Issa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Elliott</last_name>
      <phone>319-384-1628</phone>
      <email>trisha-elliott@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Bailin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nebraska Heart Institute</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Baehr</last_name>
      <phone>402-328-3939</phone>
      <email>dbaehr@neheart.com</email>
    </contact>
    <investigator>
      <last_name>Peter Gallagher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-1000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Aldrich</last_name>
      <phone>603-650-6134</phone>
      <email>brian.j.aldrich@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Kevin Kwaku</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catholic Medical Center</name>
      <address>
        <city>Manchester</city>
        <state>New Hampshire</state>
        <zip>03102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Cornelius</last_name>
      <phone>603-663-6094</phone>
      <email>elizabeth.cornelius@cmc-nh.org</email>
    </contact>
    <investigator>
      <last_name>Jamie Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaleida Health</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Daetsch</last_name>
      <phone>716-888-4848</phone>
      <email>daetsch@buffalo.edu</email>
    </contact>
    <investigator>
      <last_name>Anne Curtis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bethesda North Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Voorhorst</last_name>
      <phone>513-862-2877</phone>
      <email>anne_voorhorst@trihealth.com</email>
    </contact>
    <investigator>
      <last_name>Marshall Winner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Panko</last_name>
      <phone>216-444-6478</phone>
      <email>pankom@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Oussama Wazni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Cornell</last_name>
      <phone>610-402-9543</phone>
      <email>kristen.cornell@lvhn.org</email>
    </contact>
    <investigator>
      <last_name>Hari Joshi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HeartPlace Mid-Cities EP</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Keller</last_name>
      <phone>682-223-9120</phone>
      <email>judith.keller@heartplace.com</email>
    </contact>
    <investigator>
      <last_name>Craig Delaughter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orion Medical</name>
      <address>
        <city>Pasadena</city>
        <state>Texas</state>
        <zip>77505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Morrow</last_name>
      <phone>713-943-2800</phone>
      <email>cherie.morrow@orionmedical.net</email>
    </contact>
    <investigator>
      <last_name>Karan Bhalla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christus Trinity Mother Frances Health System</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Cushman</last_name>
      <phone>903-510-8846</phone>
      <email>carol.cushman@christushealth.org</email>
    </contact>
    <investigator>
      <last_name>Stanislav Weiner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juedisches Krankenhaus Berlin</name>
      <address>
        <city>Berlin-Mitte</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lidia Fischer</last_name>
      <phone>493049942662</phone>
      <email>lidia.fischer@jkb-online.de</email>
    </contact>
    <investigator>
      <last_name>Bogdan Muntean</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sigrun Mueller</last_name>
      <phone>497219743045</phone>
      <email>sigrun.mueller@klinikum-karlsruhe.de</email>
    </contact>
    <investigator>
      <last_name>Armin Luik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kokura Memorial Hospital</name>
      <address>
        <city>Fukuoka-ken</city>
        <zip>802-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuki Matsui</last_name>
      <phone>81935113248</phone>
      <email>matsui-y@kokurakinen.or.jp</email>
    </contact>
    <investigator>
      <last_name>Kenichi Hiroshima</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yokosuka Kyosai Hospital</name>
      <address>
        <city>Kanagawa Prefecture</city>
        <zip>238-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yasuaki Tanaka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>42601</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shin Young Lee</last_name>
      <phone>82532584628</phone>
      <email>sinyomi94@naver.com</email>
    </contact>
    <investigator>
      <last_name>Seongwook Han</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>2841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoomi Jo</last_name>
      <phone>29206710</phone>
      <email>0216yoomi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>JaeMin Shim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Princesse Grace</name>
      <address>
        <city>Monaco</city>
        <zip>98000</zip>
        <country>Monaco</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Rijo</last_name>
      <phone>37797988445</phone>
      <email>nicolas.rijo@chpg.mc</email>
    </contact>
    <investigator>
      <last_name>Decebal-Gabriel Latcu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Papworth Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0AY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzy Deeley</last_name>
      <phone>1223639761</phone>
      <email>suzy.deeley@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Claire Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Monaco</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 1, 2018</study_first_submitted>
  <study_first_submitted_qc>November 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2018</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No requests for study data have been made at this time, however Boston's Scientific's policy on data sharing can be found at http://www.bostonscientific.com/en-US/data-sharing-requests.html</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

